Professors Matthias Augustin and Sarina Elmariah evaluate how targeted therapies transform the management of prurigo nodularis, addressing the itch-scratch cycle and broader manifestations such as lesions.

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the key considerations for management of AD that is uncontrolled with topical therapies in children and the criteria to determine whether a patient is indicated for systemic therapy
Hear Dr. Ulrike von Arnim discuss the expert recommendations for monitoring patients with EoE in routine clinical practice.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.

Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.

In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.

Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025

Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.
Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.